Nordic Trip.

Study name	Nordic trip, a randomized phase 3 study in early triple negative breast cancer
Methods	Accrual: recruiting Accrual target: 1800 Multicentre, phase 3 RCT Trial is being conducted in Sweden, Denmark, Finland and Iceland Blinding: open‐label study
Participants	People with early triple‐negative breast cancer stage I (> 10 mm) to III Adjuvant or neoadjuvant: both
Interventions	Arm 1: intervention: carboplatin followed by epirubicin and cyclophosphamide (further details not provided) Arm 2: comparator(s): paclitaxel followed epirubicin and cyclophosphamide or capecitabine followed by epirubicin and cyclophosphamide
Outcomes	Primary Invasive disease‐free survival Secondary Invasive disease‐free survival in subsets of triple‐negative breast cancer and BRCA‐mutation status
Starting date	Planned start date: not specified Estimated completion date: not specified
Contact information	Contact: Niklas Loman (niklas.loman@med.lu.se)
Notes	Trial registration link: not specified Trial sponsor: not specified Funding considerations: not specified